Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Arthur M. Cohen & Associates LLC

Arthur M. Cohen & Associates LLC lowered its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 22.1% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,163 shares of the medical research company's stock after selling 4,295 shares during the quarter. Arthur M. Cohen & Associates LLC's holdings in Edwards Lifesciences were worth $1,099,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in Edwards Lifesciences by 10.4% in the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock worth $5,117,845,000 after acquiring an additional 6,537,494 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Edwards Lifesciences by 5.3% during the fourth quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock worth $2,458,601,000 after purchasing an additional 1,678,154 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Edwards Lifesciences by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company's stock valued at $1,007,520,000 after purchasing an additional 126,194 shares during the period. Fisher Asset Management LLC increased its stake in Edwards Lifesciences by 7.7% in the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company's stock valued at $723,664,000 after purchasing an additional 696,965 shares during the last quarter. Finally, Norges Bank acquired a new position in Edwards Lifesciences in the fourth quarter valued at $610,895,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Down 0.3%

NYSE:EW traded down $0.21 on Friday, reaching $77.56. The stock had a trading volume of 2,633,909 shares, compared to its average volume of 5,193,910. The company has a 50-day moving average of $73.87 and a 200 day moving average of $72.69. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market cap of $45.50 billion, a P/E ratio of 11.13, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business had revenue of $1.41 billion for the quarter, compared to analysts' expectations of $1.40 billion. During the same quarter in the previous year, the firm posted $0.66 earnings per share. The company's revenue was up 6.2% compared to the same quarter last year. On average, research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the company's stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total transaction of $797,287.50. Following the sale, the chief financial officer now owns 30,387 shares in the company, valued at $2,153,526.69. This represents a 27.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total value of $645,620.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company's stock, valued at $3,189,770.56. This trade represents a 16.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 59,012 shares of company stock valued at $4,224,717. 1.29% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a research report on Monday. Truist Financial decreased their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Wolfe Research downgraded Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Morgan Stanley increased their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 12th. Finally, Barclays boosted their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $80.20.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.